

Fellow Publications/Presentations January through December 2024

Publications

1. **Hundal J, Curley T**, Hamilton BK. Cardiovascular Considerations in Patients Undergoing Hematopoietic Cell Transplantation. *Curr Treat Options Oncol*. 2024 Aug;25(8):1027-1037. doi: 10.1007/s11864-024-01240-1. Epub 2024 Jul 25. PMID: 39052206; PMCID: PMC11329532.
2. Goel U, **Mian A**, Sauter CS. SOHO State of the Art Updates and Next Questions | Contemporary Role of Autologous Stem Cell Transplantation for the Treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma in the Era of Cellular Therapies. *Clin Lymphoma Myeloma Leuk*. 2025 Apr;25(4):219-225. doi: 10.1016/j.clml.2024.07.020. Epub 2024 Aug 3. PMID: 39214752.
3. Stuver R, **Mian A**, Brown S, et. al. BEAM versus pharmacokinetics-directed BuCyVP16 conditioning for patients with peripheral T-cell lymphoma undergoing high-dose therapy with autologous hematopoietic cell transplantation. *Am J Hematol*. 2024 Jun;99(6):1180-1183. doi: 10.1002/ajh.27291. Epub 2024 Mar 25. PMID: 38526002; PMCID: PMC11096040.
4. **Yalamanchali A**, Hassan KA. MUC1-C: The Occam Razor of Osimertinib Resistance? *J Thorac Oncol*. 2024 Mar;19(3):370-372. doi: 10.1016/j.jtho.2023.12.014. PMID: 38453323.
5. **Yalamanchali A**, Griffith C, Reddy CA, Koyfman SA, Woody NM, Campbell SR, Silver N, Scharpf J, Lorenz RR, Prendes B, Ku JA, Lamarre E, Geiger JL. Evaluating the impact of the degree of extranodal extension on outcomes in locally advanced oral cavity cancer. *Head Neck*. 2024 Sep;46(9):2340-2347. doi: 10.1002/hed.27782. Epub 2024 Apr 25. PMID: 38660928.
6. Nair KG, Kamath SD, **Chowattukunnel N**, Krishnamurthi SS. Preoperative Strategies for Locally Advanced Colon Cancer. *Curr Treat Options Oncol*. 2024 Mar;25(3):376-388. doi: 10.1007/s11864-024-01184-6. Epub 2024 Feb 13. PMID: 38349502; PMCID: PMC10894759.
7. Ornstein MC, **George L**, Wei W, et. al. Phase II Trial of Intermittent Therapy in Patients with Metastatic Renal Cell Carcinoma Treated with Front-line Ipilimumab and Nivolumab. *Clin Genitourin Cancer*. 2024 Dec;22(6):102181. doi: 10.1016/j.clgc.2024.102181. Epub 2024 Jul 31. PMID: 39208489.
8. **Trunk AD**, Guo M, Budvytyte L, Islam NS, Khera N, Hamilton BK, Amonoo HL. Hematopoietic Stem-Cell Transplantation: Exploring the Latest Advances and Gaps in Disparities, Psychosocial and Symptom Management Interventions, and Chronic Graft-Versus-Host Disease Care. *Am Soc Clin Oncol Educ Book*. 2024 Jun;44(3):e432186. doi: 10.1200/EDBK_432186. PMID: 38754066.
9. **Brooks TR**, Caimi PF. A paradox of choice: Sequencing therapy in relapsed/refractory diffuse large B-cell lymphoma. *Blood Rev*. 2024 Jan;63:101140. doi: 10.1016/j.blre.2023.101140. Epub 2023 Oct 28. PMID: 37949705.

10. Matusov Y, **Brooks T**, Burroughs-Ray D, Neupane M. Peer Review: Insights Gleaned From Observing the Editorial Process at Annals of Internal Medicine. *Ann Intern Med.* 2025 Jan;178(1):112-113. doi: 10.7326/ANNALS-24-01737. Epub 2024 Nov 19. PMID: 39556836.
11. **Brooks T**. A Record of Failures and the Dark Side of Meritocracy. *Acad Med.* 2024 Jun 1;99(6):e3. doi: 10.1097/ACM.0000000000005489. Epub 2023 Oct 9. PMID: 37816220.
12. **Delasos L**, Khorrami M, Viswanathan VS, Jazieh K, Ding Y, Mutha P, Stephans K, Gupta A, Pennell NA, Patil PD, Higgins K, Madabhushi A. Novel radiogenomics approach to predict and characterize pneumonitis in stage III NSCLC. *NPJ Precis Oncol.* 2024 Dec 24;8(1):290. doi: 10.1038/s41698-024-00790-9. PMID: 39719541; PMCID: PMC11668872.
13. Ullah F, Markouli M, Orland M, Ogbue O, **Dima D**, Omar N, Mustafa Ali MK. Large Granular Lymphocytic Leukemia: Clinical Features, Molecular Pathogenesis, Diagnosis and Treatment. *Cancers (Basel).* 2024 Mar 27;16(7):1307. doi: 10.3390/cancers16071307. PMID: 38610985; PMCID: PMC11011145.
14. **Dima D**, Davis JA, Ahmed N, Jia X, Sannareddy A, Shaikh H, Shune L, Kaur G, Khouri J, Afrough A, Strouse C, Lochner J, Mahmoudjafari Z, Raza S, Valent J, Anderson LD Jr, Anwer F, Abdallah AO, Hashmi H. Safety and Efficacy of Teclistamab in Patients with Relapsed/Refractory Multiple Myeloma: A Real-World Experience. *Transplant Cell Ther.* 2024 Mar;30(3):308.e1-308.e13. doi: 10.1016/j.jtct.2023.12.016. Epub 2023 Dec 26. PMID: 38151105.
15. Gagelmann N, **Dima D**, Merz M, Hashmi H, Ahmed N, Tovar N, Oliver-Caldés A, Stölzel F, Rathje K, Fischer L, Born P, Schäfer L, Albici AM, Schub N, Kfir-Erenfeld S, Assayag M, Asherie N, Wulf GG, Kharboutli S, Müller F, Shune L, Davis JA, Anwer F, Vucinic V, Platzbecker U, Ayuk F, Kröger N, Khouri J, Gurnari C, McGuirk J, Stepensky P, Abdallah AO, Fernández de Larrea C. Development and Validation of a Prediction Model of Outcome After B-Cell Maturation Antigen-Directed Chimeric Antigen Receptor T-Cell Therapy in Relapsed/Refractory Multiple Myeloma. *J Clin Oncol.* 2024 May 10;42(14):1665-1675. doi: 10.1200/JCO.23.02232. Epub 2024 Feb 15. PMID: 38358946; PMCID: PMC11095856.
16. Wesson W, **Dima D**, Suleman N, Saif MSI, Tabak C, Logan E, Davis JA, McGann M, Furqan F, Mohan M, Rashid A, Abdallah AO, Ullah F, Shune L, Mushtaq MU, Raza S, McGuirk J, Hamadani M, Anwer F, Hashmi H, Ahmed N. Timing of Toxicities and Non-Relapse Mortality Following CAR T Therapy in Myeloma. *Transplant Cell Ther.* 2024 Sep;30(9):876-884. doi: 10.1016/j.jtct.2024.06.012. Epub 2024 Jun 11. PMID: 38871056.
17. Merz M, **Dima D**, Hashmi H, Ahmed N, Stölzel F, Holderried TAW, Fenk R, Müller F, Tovar N, Oliver-Caldés A, Rathje K, Davis JA, Fandrei D, Vucinic V, Kharboutli S, Baermann BN, Ayuk F, Platzbecker U, Albici AM, Schub N, Schmitz F, Shune L, Khouri J, Anwer F, Raza S, McGuirk J, Mahmoudjafari Z, Green K, Khandanpour C, Teichert M, Jeker B, Hoffmann M, Kröger N, von Tresckow B, de Larrea CF, Pabst T, Abdallah AO, Gagelmann N. Bispecific antibodies targeting BCMA or GPRC5D are highly effective in relapsed myeloma after CAR T-cell therapy. *Blood Cancer J.* 2024 Dec 5;14(1):214. doi: 10.1038/s41408-024-01197-2. PMID: 39632797; PMCID: PMC11618392.
18. **Dima D**, Goel U, Sannareddy A, Ibeh N, Ullah F, Afrough A, Mazzoni S, Mehdi A, Rudoni J, Raza S, De Simone N, Williams L, Khan A, Rashid A, Rice M, Ricci K, Samaras C, Valent J, Anderson LD Jr, Anwer F, Kaur G, Khouri J. Outcomes of therapeutic plasma exchange for

the treatment of patients with multiple myeloma cast nephropathy. *Hematol Oncol*. 2024 Jul;42(4):e3293. doi: 10.1002/hon.3293. PMID: 38872511.

19. **Dima D**, Hughes M, Orland M, Ullah F, Goel U, Anwer F, Raza S, Mazzoni S, Bhutani D, Williams L, Lentzsch S, Samaras C, Valent J, Chakraborty R, Khouri J. Outcomes of venetoclax-based therapy in patients with t(11;14) light chain amyloidosis after failure of daratumumab-based therapy. *Amyloid*. 2024 Sep;31(3):195-201. doi: 10.1080/13506129.2024.2366806. Epub 2024 Jul 2. PMID: 38956891.
20. Goel U, **Dima D**, Davis J, Ahmed N, Shaikh H, Lochner J, Abdallah AO, Khouri J, Hashmi H, Anwer F. Safety and efficacy of B cell maturation antigen-directed CAR T-cell therapy in patients with relapsed/refractory multiple myeloma and concurrent light chain amyloidosis. *Eur J Haematol*. 2024 Dec;113(6):817-823. doi: 10.1111/ejh.14293. Epub 2024 Aug 27. PMID: 39189919.
21. Khouri J, **Dima D**, Li H, Hansen D, Sidana S, Shune L, Anwer F, Sborov D, Wagner C, Kocoglu MH, Atrash S, Voorhees P, Peres L, Hovanky V, Simmons G, Williams L, Raza S, Afrough A, Anderson LD Jr, Ferreri C, Hashmi H, Davis J, McGuirk J, Goldsmith S, Borogovac A, Lin Y, Midha S, Nadeem O, Locke FL, Baz R, Hamilton B, Alsina M, Sauter C, Patel K, Kaur G. Absolute Lymphocyte Count and Outcomes of Multiple Myeloma Patients Treated with Idecabtagene Vicleucel: The US Myeloma Immunotherapy Consortium Real- World Experience. *Transplant Cell Ther*. 2024 Aug;30(8):790.e1-790.e16. doi: 10.1016/j.jtct.2024.05.025. Epub 2024 Jun 2. PMID: 38834151.
22. **Dima D**, Abdallah AO, Davis JA, Awada H, Goel U, Rashid A, DeJarnette S, Anwer F, Shune L, Raza S, Mahmoudjafari Z, Williams L, Faiman B, McGuirk JP, Sauter CS, Ahmed N, Khouri J, Hashmi H. Impact of Extraosseous Extramedullary Disease on Outcomes of Patients with Relapsed-Refractory Multiple Myeloma receiving Standard-of-Care Chimeric Antigen Receptor T-Cell Therapy. *Blood Cancer J*. 2024 May 31;14(1):90. doi: 10.1038/s41408-024-01068-w. PMID: 38821914; PMCID: PMC11143360.
23. **Dima D**, Rashid A, Davis JA, Shune L, Abdallah AO, Li H, DeJarnette S, Khouri J, Williams L, Hashmi H, Raza S, McGuirk J, Anwer F, Ahmed N. Efficacy and safety of idecabtagene vicleucel in patients with relapsed-refractory multiple myeloma not meeting the KarMMa-1 trial eligibility criteria: A real-world multicentre study. *Br J Haematol*. 2024 Apr;204(4):1293-1299. doi: 10.1111/bjh.19302. Epub 2024 Jan 23. PMID: 38263627.
24. **Dima D**, Khouri J. The role of therapeutic plasma exchange in plasma cell disorders. *Ann Hematol*. 2024 Oct;103(10):3941-3946. doi: 10.1007/s00277-024-05712-0. Epub 2024 Apr 1. PMID: 38558184; PMCID: PMC11512890.
25. Habib MH, Tiger YKR, **Dima D**, Schlögl M, McDonald A, Mazzoni S, Khouri J, Williams L, Anwer F, Raza S. Role of Palliative Care in the Supportive Management of AL Amyloidosis-A Review. *J Clin Med*. 2024 Mar 29;13(7):1991. doi: 10.3390/jcm13071991. PMID: 38610755; PMCID: PMC11012321.
26. **Dima D**, Sauter CS. Biological Age is No Barrier for Adult Patients Undergoing CAR T for Non-Hodgkin's Lymphoma or Multiple Myeloma. *Transplant Cell Ther*. 2024 May;30(5):462-464. doi: 10.1016/j.jtct.2024.04.002. PMID: 38677789.

27. **Dima D**, Lopetegui-Lia N, Ogbue O, Osantowski B, Ullah F, Jia X, Song JM, Gastman B, Isaacs J, Kennedy LB, Funchain P. Real-world outcomes of patients with resected stage III melanoma treated with adjuvant therapies. *Cancer Med*. 2024 Jun;13(12):e7257. doi: 10.1002/cam4.7257. PMID: 39031560; PMCID: PMC11190025.
28. Jaber-Douraki M, Xu X, **Dima D**, Ailawadhi S, Anwer F, Mazzoni S, Valent J, Habib MH, Riviere JE, Raza S. Global disparities in drug-related adverse events of patients with multiple myeloma: a pharmacovigilance study. *Blood Cancer J*. 2024 Dec 20;14(1):223. doi: 10.1038/s41408-024-01206-4. PMID: 39706832; PMCID: PMC11661995.
29. Davis JA, **Dima D**, Ahmed N, DeJarnette S, McGuirk J, Jia X, Raza S, Khouri J, Valent J, Anwer F, Abdallah AO, Hashmi H. Impact of Frailty on Outcomes after Chimeric Antigen Receptor T Cell Therapy for Patients with Relapsed/Refractory Multiple Myeloma. *Transplant Cell Ther*. 2024 Mar;30(3):298-305. doi: 10.1016/j.jtct.2023.12.015. Epub 2023 Dec 22. PMID: 38142943.
30. **Jayakrishnan TT**, Sangwan N, Barot SV, Farha N, Mariam A, Xiang S, Aucejo F, Conces M, Nair KG, Krishnamurthi SS, Schmit SL, Liska D, Rotroff DM, Khorana AA, Kamath SD. Multi-omics machine learning to study host-microbiome interactions in early-onset colorectal cancer. *NPJ Precis Oncol*. 2024 Jul 17;8(1):146. doi: 10.1038/s41698-024-00647-1. PMID: 39020083; PMCID: PMC11255257.
31. **Jayakrishnan T**, Mariam A, Farha N, Rotroff DM, Aucejo F, Barot SV, Conces M, Nair KG, Krishnamurthi SS, Schmit SL, Liska D, Khorana AA, Kamath SD. Plasma metabolomic differences in early-onset compared to average-onset colorectal cancer. *Sci Rep*. 2024 Feb 21;14(1):4294. doi: 10.1038/s41598-024-54560-5. PMID: 38383634; PMCID: PMC10881959.
32. **Jayakrishnan T**, Baca Y, Xiu J, Patel M, Weinberg BA, Lou E, Datta J, Khushman M, Gulhati P, Goel S, Biachi de Castria T, Florou V, Nair KG, Kamath SD, Khorana AA. Molecular Differences With Therapeutic Implications in Early-Onset Compared With Average-Onset Biliary Tract Cancers. *JCO Precis Oncol*. 2024 Aug;8:e2400138. doi: 10.1200/PO.24.00138. PMID: 39102632.
33. **Jayakrishnan T**, Yadav D, Huffman BM, Cleary JM. Immunological Checkpoint Blockade in Anal Squamous Cell Carcinoma: Dramatic Responses Tempered By Frequent Resistance. *Curr Oncol Rep*. 2024 Aug;26(8):967-976. doi: 10.1007/s11912-024-01564-z. Epub 2024 Jun 11. PMID: 38861124.

Poster Presentations/Abstracts

1. **Awada H**, Druma A, Guamera L, et. al. Counterpoising immune pressure and privilege: paroxysmal nocturnal hemoglobinuria evolutionary dynamics. ASH Annual Meeting. San Diego, CA. December 2024. (Poster)
2. **Basali D**, Hurwitz H, et. al. A Pilot Screening and Patient Navigation Program for Early Detection of Multiple Myeloma to Address Cancer Disparities. ASH Annual Meeting. San Diego, CA. December 2024. (Poster)
3. **Basali D**, Zureigat H, Nurse D, et. al. Real World Data on Safety and Efficacy of low dose direct oral anticoagulants (DOACs) for venous thromboembolism prophylaxis in newly

diagnosed Multiple Myeloma. International Myeloma Society. September 2024. Rio de Janeiro Brazil. (Poster)

4. **Basali D.** Zureigat H, Nurse D, et. al. Efficacy of low dose direct oral anticoagulants (DOACs) for venous thromboembolism prophylaxis in newly diagnosed Multiple Myeloma. ASCO Annual Meeting. Chicago IL. May 2024. (Poster)
5. **Delasos L.**, et. al. Effect of tumor burden on survival in patients with stage IV EGFR-mutant NSCLC receiving osimertinib monotherapy. ASCO Annual Meeting. Chicago IL. May 2024. (Poster)
6. **El-Asmar J.**, et. al. A Comprehensive Analysis of FLT3 Mutation Profiles and Clinical Outcomes in Adult Patients with Acute Myeloid Leukemia: A Single Institution Experience. ASH Annual Meeting. San Diego CA. December 2024. (Poster)
7. **Hundal J, et. al.** Cancer burden in South Asians in the United States: Epidemiologic report using Surveillance, Epidemiology, and End Results (SEER) program. ASCO Annual Meeting. Chicago IL. May 2024. (Oral)
8. **Hundal J.**, et. al. Comparing cancer epidemiology trends between South Asian Americans and Whites in the United States using Surveillance, Epidemiology, and End Results (SEER) program. ASCO Annual Meeting. Chicago IL. May 2024. (Poster)
9. **Hundal J, et. al.** Integrating lifestyle medicine into cancer care: A new paradigm. ASCO Breakthrough Meeting. Yokohama, Japan. August 2024. (Poster)
10. **Hundal J, et. al.** Racial-Ethnic Disparities in Cancer Survival and Stages: A Focus on South Asian Americans. 17th AACR Conference on The Science of Cancer Health Disparities. Los Angeles, CA. September 2024. (Poster)
11. **Hundal J.**, Ballambat N, Swede H, et. al. Predictors of receiving Work Accommodations among employed Breast Cancer Survivors with Adult and Child Dependents at Home. ASCO Quality Care Symposium. San Francisco, CA. September 2024. (Poster)
12. **Hundal J.**, et. al. Development and Implementation of the Lifestyle Medicine Cancer Toolkit for Risk Reduction and Survivorship. American College of Lifestyle Medicine Conference. Orlando, FL. October 2024. (Poster)
13. **Hundal J.**, et. al. AI Powered Breast Cancer Survivorship Support: A Comparative Analysis of ChatGPT and Gemini in Providing Evidence-Based Lifestyle Guidance. San Antonio Breast Conference Symposium. San Antonio TX. December 2024 (Poster)
14. **Hundal J.**, et. al. Impact of cardiometabolic comorbidities on outcomes in early-stage triple-negative breast cancer patients treated with neoadjuvant chemo-immunotherapy (Keynote-522 regimen): A retrospective analysis. San Antonio Breast Cancer Symposium, San Antonio TX. December 2024. (Poster)
15. **Hundal J.**, et. al. Impact of obesity, skeletal muscle index, and comorbidities on chemotherapy-related outcomes in early breast cancer: A retrospective subanalysis. Hundal J., Aleixo GFP.,

Valente S., Wei PH., Chen W., Moore H., San Antonio Breast Cancer Symposium. San Antonio TX. December 2024. (Poster)

16. **Jayakrishnan T**, et. al. Molecular differences with therapeutic implications in early-onset compared to average-onset cholangiocarcinoma. ASCO Gastrointestinal Cancers Symposium. San Francisco CA. January 2024. (Poster)
17. **Jayakrishnan T**, et. al. Tumor microbiome differences in early-onset versus average-onset pancreatic adenocarcinoma. ASCO Annual Meeting. Chicago, IL. May 2024. (Oral)
18. **Mian A**, et. al. Neighborhood Socioeconomic Disadvantage and Distance from Treatment Center Do Not Impact Survival Outcomes of Patients with Non-Hodgkin's Lymphoma (NHL) and Multiple Myeloma (MM) Treated with CAR T-Cell Therapies. Tandem ASTCT & CIBMTR Meeting. San Antonio TX. February 2024. (Poster)
19. **Mian A**, et al. Phase I clinical trial of Rituximab and Tafasitamab in combination with allogeneic NK cells for treatment of relapsed/refractory B-cell non-Hodgkin Lymphoma. ASTCT CRTC (Clinical Research Training Course). Park City Utah. July 2024 (Poster)
20. **Mian A**, et al. Phase I clinical trial of Rituximab and Tafasitamab in combination with allogeneic NK cells for treatment of relapsed/refractory B-cell non-Hodgkin Lymphoma. ASCO/AACR Methods in Clinical Cancer Research Workshop. La Jolla CA. July 2024. (Poster)
21. **Trunk A**, Chen Y, Hamilton B, et. al. Reduced Intensity Versus Myeloablative Allogeneic Cell Transplant for Chronic Myelomonocytic Leukemia: A Single Institution Experience. Tandem ASTCT & CIBMTR Meeting. San Antonio, TX. February 2024. (Poster)
22. **Trunk A**, et. al. Reduced Intensity Versus Myeloablative Allogeneic Hematopoietic Cell Transplant for Myelofibrosis: A Single Institution Experience. Tandem ASTCT & CIBMTR Meeting. San Antonio, TX. February 2024. (Poster)
23. **Trunk A**, et. al. Impact of Allogeneic Hematopoietic Cell Transplantation on Neurocognitive Function. Tandem ASTCT & CIBMTR Meeting. San Antonio, TX. February 2024. (Poster)
24. **Trunk A**, et. al. Factors associated with Platelet Engraftment Following Allogeneic Hematopoietic Cell Transplantation. ASH Annual Meeting. San Diego, CA. December 2024. (Poster)
25. **Trunk A**, Li H, Giannetti K, et. al. Impact of Allogeneic Hematopoietic Cell Transplant on Neurocognitive Function. Tandem ASTCT & CIBMTR Meeting. San Antonio, TX. February 2024. (Poster)
26. **Trunk A**, Li H, Kalaycio M, Sobecks R, et. al. Factors Associated with Platelet Engraftment Following Allogeneic Hematopoietic Cell Transplantation. ASH Annual Meeting. San Diego, CA. December 2024 (Poster)

27. **Velimirovic M**, et. al. Clinicopathologic and genomic characteristics of patients with advanced ovarian, breast, and prostate cancer treated with poly (ADP-ribose) polymerase inhibitors (PARPi) in a real-world setting. ASCO Annual Meeting. Chicago IL. May 2024. (Poster)